Related Experiment Video

Updated: Sep 23, 2026

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell

Irene Sulzbacher1, Peter Birner, Margit Träxler

  • 1Clinical Institute of Pathology, University of Vienna Medical School, Vienna, Austria.

American Journal of Clinical Pathology
|July 18, 2003
PubMed

Insights

High platelet-derived growth factor-alpha alpha receptor expression in clear cell renal cell carcinoma (ccRCC) correlates with adverse outcomes. This suggests the PDGF receptor-factor interaction may be a target for new therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Platelet-derived growth factors (PDGFs) are crucial for cellular functions, binding to tyrosine kinase receptors.
  • The PDGF-alpha alpha receptor specifically binds PDGF proteins, mediating growth stimulation.
  • Understanding PDGF signaling in renal cell carcinoma (RCC) is vital for treatment strategies.

Purpose of the Study:

  • To investigate the expression of PDGF-alpha alpha receptor and its ligand PDGF-AA in human clear cell renal cell carcinoma (ccRCC).
  • To correlate PDGF-alpha alpha receptor and PDGF-AA expression with clinicopathologic parameters and patient outcomes in ccRCC.
  • To evaluate the prognostic significance of PDGF signaling in ccRCC.

Main Methods:

  • Immunohistochemical analysis was employed to assess the expression of PDGF-alpha alpha receptor and PDGF-AA in ccRCC tissues.
  • Expression levels were quantified and correlated with tumor grade and other clinicopathologic parameters.
  • Statistical analyses, including Mann-Whitney test and log-rank test, were used to determine significance.

Main Results:

  • Mean expression of PDGF-alpha alpha receptor was 38.8% and PDGF-AA was 18.4% in ccRCC.
  • Significantly higher PDGF-alpha alpha receptor expression was observed in high-grade (grade 3 and 4) ccRCC compared to low-grade (grade 1 and 2) tumors (P = .027).
  • High PDGF-alpha alpha receptor expression correlated with tumor progression (P = .0253), while PDGF-AA expression showed no prognostic influence.

Conclusions:

  • Elevated PDGF-alpha alpha receptor expression in ccRCC is associated with adverse clinical outcomes.
  • The PDGF receptor-factor interaction represents a potential therapeutic target for novel treatment strategies in ccRCC.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...